Skip to main content

Table 1 Patient demographics between groups

From: Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study

Variable CPB (n = 124) CPA (n = 122) p-value
Age (years) 62.1 ± 7.59 62.2 ± 6.84 0.183a
BMI 24.5 ± 5.31 25.6 ± 6.19 0.102a
Haemoglobin < 11 g/dLc, n (%) 36 (29.0) 32 (26.2) 0.624b
Histology, n (%)    0.439b
 Squamous 79 (63.7) 72 (59.0)  
 Adenocarcinoma 34 (27.4) 37 (30.3)  
 Adenosquamous 11 (8.9) 13 (10.7)  
IVB cervical cancer, n (%)    0.533b
 Asymptomatic CNS metastasis 45 (36.3) 49 (40.2)  
 Without CNS metastasis 79 (63.7) 73 (59.8)  
Duration of drug (months) 17.8 ± 7.46 17.4 ± 7.63 0.219a
ECOG status, n (%)    0.663b
 0d 46 (37.1) 42 (34.4)  
 1e 78 (62.9) 80 (65.6)  
GOG statusf, n (%)    0.672b
 0f 49 (39.5) 45 (36.9)  
 1g 75 (60.5) 77 (63.1)  
No. of metastatic sites, n (%)    0.445b
 3 38 (30.6) 30 (27.8)  
  > 3 71 (57.3) 78 (62.0)  
 Unknown 15 (12.1) 14 (10.2)  
  1. aAnalysed using an independent samples t-test; bAnalysed using the Mann-Whitney U test;
  2. cHaemoglobin level was calculated one week before the start of CPB or CPA; 0d, Fully active, able to carry on all pre-disease performance without restriction; 1e, Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work; 0f: fully active; 1g: restricted in physically strenuous activities, but ambulatory. CPB cisplatin-paclitaxel chemotherapy plus bevacizumab, CPA cisplatin-paclitaxel chemotherapy alone, BMI body mass index, CNS central nervous system, ECOG Eastern Collaborative Oncology Group, GOG Gynecologic Oncology Group
\